Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, 5S ribosomal pseudogene 20 is a processed pseudogene derived from the 5S ribosomal RNA gene family on human chromosome 1p31.1[2][3]. Processed pseudogenes arise via retrotransposition of mRNA transcripts, lack introns and canonical regulatory elements, are generally non-protein-coding, and often accumulate mutations that render them non-functional[1][3][5]. While some pseudogenes can produce RNA transcripts that regulate parent gene expression through antisense interference or siRNA production, RNA5SP20 itself has not been described as functional in these processes[1][6]. Pseudogenes like RNA5SP20 primarily serve as molecular fossils of gene duplication and retrotransposition events and are classified under junk DNA, although they may rarely acquire regulatory roles[1][4][5]. RNA5SP20 is not a therapeutic target in medicine and does not interact directly with drugs or serve as a biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 5S ribosomal pseudogene 20 (RNA5SP20).